Ligand Pharmaceuticals Inc (LGND) stock
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Earnings
Ligand Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ligand Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | $78.70M | -31.9% | -$1.43 | $2.67 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $63.70M | +33.8% | $2.22 | $2.37 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $51.70M | +14.1% | -$0.67 | $1.63 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $59.70M | +39.5% | $2.12 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $115.50M | +123.0% | $5.68 | $3.09 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $47.60M | +14.7% | $0.24 | $1.60 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $45.30M | +46.1% | -$2.21 | $1.33 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $42.80M | +52.3% | -$1.64 | $1.27 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $51.80M | +57.4% | -$0.39 | $1.84 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $41.50M | +57.2% | -$2.88 | $1.40 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $31.00M | -29.5% | $4.75 | $3.84 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024before the open | $28.10M | -44.2% | $1.03 | $1.38 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $32.90M | -50.2% | -$0.74 | $1.02 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $26.40M | -54.0% | $0.13 | $1.42 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $44.00M | -3.7% | $2.43 | $2.28 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023after the close | $50.40M | -30.5% | -$0.86 | $1.36 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022after the close | $66.10M | +2.0% | $0.02 | $1.31 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | $57.40M | – | -$0.05 | $1.03 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $45.70M | – | -$0.91 | $0.76 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 17, 2022after the close | $72.50M | – | -$0.30 | $1.80 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $64.80M | – | $0.80 | $1.58 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 3, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 3, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 20, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ligand Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| royalty revenue | FY2026 | $225.00M – $250.00M | $10.00M – $20.00M | Lowered | Aug 6, 2026 |
| Total revenue | FY2026 | $270.00M – $310.00M | – | New | Oct 29, 2026 |
| Adjusted earnings per diluted sharenon-GAAP | FY2026 | $9.50 – $9.75 | – | New | Oct 29, 2026 |
| Adjusted earnings per diluted sharenon-GAAP | FY2026 | $9.00 – $9.50 | $8.50 – $9.50 | Raised | Aug 6, 2026 |
| Adjusted Net Incomenon-GAAP | FY2026 | $195.00M – $206.00M | – | New | Aug 6, 2026 |
| Captisol sales | FY2026 | $35.00M – $40.00M | – | Lowered | Oct 29, 2026 |
| Contract revenue | FY2026 | $10.00M – $20.00M | – | Lowered | Oct 29, 2026 |
| GAAP Net IncomeGAAP | FY2026 | $107.00M – $118.00M | – | New | Aug 6, 2026 |
| Royalty revenue | FY2026 | $225.00M – $250.00M | – | New | Oct 29, 2026 |
Guidance vs results
The last range Ligand Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $225.00M – $235.00M | $268.10MΣ4Q | Above range |
Guidance history
Every forecast Ligand Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Adjusted earnings per diluted share | FY2026 | $9.50 – $9.75 | New |
| Oct 29, 2026 | Royalty revenue | FY2026 | $225.00M – $250.00M | New |
| Oct 29, 2026 | Captisol sales | FY2026 | $35.00M – $40.00M | Lowered |
| Oct 29, 2026 | Contract revenue | FY2026 | $10.00M – $20.00M | Lowered |
| Oct 29, 2026 | Total revenue | FY2026 | $270.00M – $310.00M | New |
| Aug 6, 2026 | Adjusted earnings per diluted share | FY2026 | $9.00 – $9.50 | Raised |
| Aug 6, 2026 | Adjusted Net Income | FY2026 | $195.00M – $206.00M | New |
| Aug 6, 2026 | GAAP Net Income | FY2026 | $107.00M – $118.00M | New |
| Aug 6, 2026 | royalty revenue | FY2026 | $225.00M – $250.00M | Lowered |
| Aug 6, 2026 | Contract revenue | FY2026 | $10.00M – $20.00M | Lowered |
| Aug 6, 2026 | Total revenue | FY2026 | $270.00M – $310.00M | Raised |
| Aug 6, 2026 | Revenue from sales of Captisol | FY2026 | $35.00M – $40.00M | Lowered |
| May 7, 2026 | adjusted earnings per diluted share | FY2026 | $8.50 – $9.50 | Raised |
| May 7, 2026 | contract revenue | FY2026 | $10.00M – $20.00M | Lowered |
| May 7, 2026 | royalty revenue | FY2026 | $225.00M – $250.00M | Lowered |
| May 7, 2026 | total revenue | FY2026 | $270.00M – $310.00M | Raised |
| May 7, 2026 | Revenue from sales of Captisol | FY2026 | $35.00M – $40.00M | Lowered |
| Feb 26, 2026 | adjusted earnings per diluted share | FY2026 | $8.00 – $9.00 | New |
| Feb 26, 2026 | contract revenue | FY2026 | $10.00M – $20.00M | Lowered |
| Feb 26, 2026 | total revenue | FY2026 | $245.00M – $285.00M | Raised |
| Feb 26, 2026 | revenue from sales of Captisol | FY2026 | $35.00M – $40.00M | Lowered |
| Feb 26, 2026 | royalty revenue | FY2026 | $200.00M – $225.00M | New |
| Nov 6, 2025 | core adjusted earnings per diluted share | FY2025 | $7.40 – $7.65 | New |
| Nov 6, 2025 | Sales of Captisol | FY2025 | $40.00M | Lowered |
| Nov 6, 2025 | Royalties | FY2025 | $147.00M – $157.00M | New |
| Nov 6, 2025 | core contract revenue | FY2025 | $38.00M | New |
| Nov 6, 2025 | total core revenue | FY2025 | $225.00M – $235.00M | New |
| Aug 7, 2025 | adjusted earnings per diluted share | FY2025 | $6.70 – $7.00 | Raised |
| Aug 7, 2025 | Royalties | FY2025 | $140.00M – $150.00M | New |
| Aug 7, 2025 | Sales of Captisol | FY2025 | $35.00M – $40.00M | Lowered |
| Aug 7, 2025 | contract revenue | FY2025 | $25.00M – $35.00M | Lowered |
| Aug 7, 2025 | total revenue | FY2025 | $200.00M – $225.00M | Raised |
| May 8, 2025 | adjusted earnings per diluted share | FY2025 | $6.00 – $6.25 | Reaffirmed |
| May 8, 2025 | total revenue | FY2025 | $180.00M – $200.00M | Raised |
| May 8, 2025 | contract revenue | FY2025 | $10.00M – $20.00M | Lowered |
| May 8, 2025 | revenue from sales of Captisol | FY2025 | $35.00M – $40.00M | Lowered |
| May 8, 2025 | royalty revenue | FY2025 | $135.00M – $140.00M | Lowered |
| Feb 27, 2025 | adjusted earnings per diluted share | FY2025 | $6.00 – $6.25 | New |
| Feb 27, 2025 | total revenue forecast | FY2025 | $180.00M – $200.00M | New |
| Nov 7, 2024 | core adjusted earnings per diluted share | FY2024 | $5.50 – $5.70 | Raised |
| Nov 7, 2024 | sales of Captisol | FY2024 | $27.00M – $29.00M | Lowered |
| Nov 7, 2024 | total revenue | FY2024 | $160.00M – $165.00M | Raised |
| Nov 7, 2024 | Royalties | FY2024 | $105.00M – $108.00M | Lowered |
| Nov 7, 2024 | contract revenue | FY2024 | $28.00M | Narrowed |
| Aug 6, 2024 | Core adjusted earnings per diluted share | FY2024 | $5.00 – $5.50 | Raised |
| Aug 6, 2024 | contract revenue | FY2024 | $15.00M – $25.00M | Lowered |
| Aug 6, 2024 | royalties | FY2024 | $100.00M – $105.00M | Raised |
| Aug 6, 2024 | sales of Captisol | FY2024 | $25.00M – $27.00M | Lowered |
| Aug 6, 2024 | total revenue forecast | FY2024 | $140.00M – $157.00M | Raised |
| May 7, 2024 | core adjusted earnings per diluted share | FY2024 | $4.25 – $4.75 | Reaffirmed |
| May 7, 2024 | royalties | FY2024 | $90.00M – $95.00M | Raised |
| May 7, 2024 | sales of Captisol | FY2024 | $25.00M – $27.00M | Lowered |
| May 7, 2024 | contract revenue | FY2024 | $15.00M – $20.00M | Lowered |
| May 7, 2024 | total revenue | FY2024 | $130.00M – $142.00M | Reaffirmed |
| Feb 27, 2024 | adjusted earnings per diluted share | FY2024 | $4.25 – $4.75 | New |
| Feb 27, 2024 | royalties | FY2024 | $90.00M – $95.00M | New |
| Feb 27, 2024 | sales of Captisol | FY2024 | $25.00M – $27.00M | Lowered |
| Feb 27, 2024 | contract revenue | FY2024 | $15.00M – $20.00M | Lowered |
| Feb 27, 2024 | total revenue forecast | FY2024 | $130.00M – $142.00M | New |
| Nov 8, 2023 | adjusted diluted EPS | FY2023 | $5.25 – $5.40 | Raised |
| Nov 8, 2023 | contract revenue | FY2023 | $17.00M | Lowered |
| Nov 8, 2023 | Sales of Captisol | FY2023 | $27.00M – $28.00M | Raised |
| Nov 8, 2023 | royalties | FY2023 | $82.00M – $84.00M | Raised |
| Nov 8, 2023 | revenue | FY2023 | $126.00M – $129.00M | Raised |
| Aug 8, 2023 | adjusted diluted EPS | FY2023 | $4.85 – $5.00 | Raised |
| Aug 8, 2023 | royalties | FY2023 | $78.00M – $82.00M | Raised |
| Aug 8, 2023 | Sales of Captisol | FY2023 | $24.00M | Lowered |
| Aug 8, 2023 | contract revenue | FY2023 | $22.00M | Lowered |
| Aug 8, 2023 | revenue | FY2023 | $124.00M – $128.00M | Reaffirmed |
| May 4, 2023 | diluted EPS | FY2023 | $4.60 – $4.75 | Raised |
| May 4, 2023 | royalties | FY2023 | $78.00M – $82.00M | Raised |
| May 4, 2023 | sales of Captisol | FY2023 | $21.00M | Lowered |
| May 4, 2023 | contract revenue | FY2023 | $25.00M | Raised |
| May 4, 2023 | total revenue | FY2023 | $124.00M – $128.00M | Raised |
| Feb 22, 2023 | adjusted diluted EPS | FY2023 | $3.30 – $3.45 | New |
| Feb 22, 2023 | cash operating expenses | FY2023 | $43.00M | New |
| Feb 22, 2023 | royalties | FY2023 | $74.00M – $78.00M | New |
| Feb 22, 2023 | sales of Captisol | FY2023 | $21.00M | Lowered |
| Feb 22, 2023 | contract revenue | FY2023 | $25.00M | Raised |
| Feb 22, 2023 | total revenue | FY2023 | $120.00M – $124.00M | New |
| Nov 7, 2022 | total company adjusted earnings per diluted share | FY2022 | $4.30 – $4.45 | Raised |
| Nov 7, 2022 | total revenue | FY2022 | $184.00M – $189.00M | Raised |
| Aug 8, 2022 | combined company adjusted earnings per diluted share | FY2022 | $2.40 – $3.00 | Raised |
| Aug 8, 2022 | total revenue | FY2022 | $169.00M – $188.00M | Raised |
| May 4, 2022 | full company adjusted earnings per diluted share | FY2022 | $1.70 – $2.20 | New |
| May 4, 2022 | total revenue | FY2022 | $147.00M – $172.00M | Reaffirmed |
| Feb 17, 2022 | royalties | FY2022 | $55.00M – $60.00M | New |
| Feb 17, 2022 | material sales | FY2022 | $40.00M – $50.00M | Lowered |
| Feb 17, 2022 | contract revenue | FY2022 | $52.00M – $62.00M | Raised |
| Feb 17, 2022 | total revenue | FY2022 | $147.00M – $172.00M | New |
| Nov 9, 2021 | adjusted earnings per diluted share | FY2021 | $5.80 – $6.05 | New |
| Nov 9, 2021 | total revenues | FY2021 | $265.00M – $275.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ligand Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- News
- News
- News
- Results
- News
- News
- Results
- Results
- News
- News
See a number that looks wrong?